Control Bionics Ltd. (CBL) AI Stock Analysis

• Market Cap: AU$11.78M
• Dividend Yield: N/A
• Average Volume (3M): 131.68K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.38
• Revenue Growth: -7.44%
• EPS Growth: 30.34%
• Country: AU
• Employees: 25
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Devices
• EPS (TTM): -0.01
• Shares Outstanding: 294,611,100
• 10 Day Avg. Volume: 34,908
• 30 Day Avg. Volume: 131,682
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: AU$0.00 ▼(-100.00%Downside)

Control Bionics Ltd. faces significant financial challenges with declining revenues and high losses, which are the most critical factors affecting its score. Despite technical indicators showing upward momentum, the overbought RSI signals potential volatility. The lack of profitability as indicated by the negative P/E ratio further weighs down the overall score.

Control Bionics Ltd. Business Overview & Revenue Model

Company Description

Control Bionics Ltd. (CBL) is a healthcare technology company specializing in assistive communication devices for individuals with speech and movement disabilities. Operating within the medical and assistive technology sectors, CBL develops and markets innovative products that enable users to communicate through brain-computer interface technology and electromyography, providing enhanced quality of life for those with conditions such as ALS, spinal cord injuries, and cerebral palsy.

How the Company Makes Money

Control Bionics Ltd. makes money primarily through the sale of its assistive communication devices and related accessories. The company generates revenue by marketing its products directly to consumers, healthcare institutions, and through distribution partnerships. Key revenue streams include the NeuroNode technology, which combines brain-computer interface and electromyography to allow users to control devices with minimal muscle movement. The company may also engage in partnerships with healthcare providers and institutions for product trials and adoption, further contributing to its earnings.

Control Bionics Ltd. Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	5.13M	5.44M	4.38M	3.93M	3.10M
Gross Profit	3.67M	3.50M	2.40M	2.50M	215.51K
EBITDA	-5.01M	-5.14M	-5.58M	-3.40M	-989.96K
Net Income	-5.91M	-5.63M	-6.11M	-4.19M	-1.01M
Balance Sheet
Total Assets	9.03M	8.70M	13.44M	18.35M	20.51M
Cash, Cash Equivalents and Short-Term Investments	980.76K	935.50K	5.21M	12.33M	15.60M
Total Debt	961.74K	128.50K	284.82K	14.87K	46.00K
Total Liabilities	2.76M	1.55M	1.51M	1.19M	387.00K
Stockholders Equity	6.27M	7.15M	11.92M	17.16M	20.13M
Cash Flow
Free Cash Flow	-5.38M	-4.98M	-5.75M	-4.04M	-1.17M
Operating Cash Flow	-4.91M	-4.53M	-5.60M	-3.99M	-864.05K
Investing Cash Flow	-473.09K	-457.54K	-147.74K	-53.40K	-301.85K
Financing Cash Flow	5.43M	706.43K	-87.33K	14.92M	1.79M

Control Bionics Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CBL, the sentiment is Positive. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.03, and below the 200-day MA of 0.05, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 79.38 is Negative, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CBL.

Control Bionics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$17.07B	5.63	-7.44%	2.87%	11.55%	-28.15%
CBL	48 Neutral	AU$11.78M	―	-98.08%	―	-7.44%	30.34%
ADR	47 Neutral	AU$8.98M	―	-375.15%	―	-59.01%	17.13%
AT1	47 Neutral	AU$14.97M	―	-61.15%	―	35.63%	18.55%
UCM	46 Neutral	AU$2.86M	―	-117.20%	―	2.91%	13.51%
HMD	45 Neutral	€10.51M	―	-321.94%	―	-39.97%	55.29%
IRX	38 Underperform	AU$8.96M	―	-191.40%	―	―	19.74%

Control Bionics Ltd. Corporate Events

Control Bionics Limited Announces Cessation of Securities

Control Bionics Limited announced the cessation of 967,720 securities due to the expiry of options or other convertible securities without exercise or conversion as of February 28, 2025. This announcement may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and market positioning.

Control Bionics to Host Investor Webinar Amid Product Expansion

Control Bionics Limited announced an investor webinar to discuss its quarterly results and recent advancements. The company is enhancing its market position with innovative products like the NeuroNode and DROVE, and is expanding into new sectors with the NeuroStrip®, potentially impacting its operations and stakeholder interests.